Cargando…

A phenome-guided drug repositioning through a latent variable model

BACKGROUND: The phenome represents a distinct set of information in the human population. It has been explored particularly in its relationship with the genome to identify correlations for diseases. The phenome has been also explored for drug repositioning with efforts focusing on the search space f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisgin, Halil, Liu, Zhichao, Fang, Hong, Kelly, Reagan, Xu, Xiaowei, Tong, Weida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137076/
https://www.ncbi.nlm.nih.gov/pubmed/25103881
http://dx.doi.org/10.1186/1471-2105-15-267
_version_ 1782331068105359360
author Bisgin, Halil
Liu, Zhichao
Fang, Hong
Kelly, Reagan
Xu, Xiaowei
Tong, Weida
author_facet Bisgin, Halil
Liu, Zhichao
Fang, Hong
Kelly, Reagan
Xu, Xiaowei
Tong, Weida
author_sort Bisgin, Halil
collection PubMed
description BACKGROUND: The phenome represents a distinct set of information in the human population. It has been explored particularly in its relationship with the genome to identify correlations for diseases. The phenome has been also explored for drug repositioning with efforts focusing on the search space for the most similar candidate drugs. For a comprehensive analysis of the phenome, we assumed that all phenotypes (indications and side effects) were inter-connected with a probabilistic distribution and this characteristic may offer an opportunity to identify new therapeutic indications for a given drug. Correspondingly, we employed Latent Dirichlet Allocation (LDA), which introduces latent variables (topics) to govern the phenome distribution. RESULTS: We developed our model on the phenome information in Side Effect Resource (SIDER). We first developed a LDA model optimized based on its recovery potential through perturbing the drug-phenotype matrix for each of the drug-indication pairs where each drug-indication relationship was switched to “unknown” one at the time and then recovered based on the remaining drug-phenotype pairs. Of the probabilistically significant pairs, 70% was successfully recovered. Next, we applied the model on the whole phenome to narrow down repositioning candidates and suggest alternative indications. We were able to retrieve approved indications of 6 drugs whose indications were not listed in SIDER. For 908 drugs that were present with their indication information, our model suggested alternative treatment options for further investigations. Several of the suggested new uses can be supported with information from the scientific literature. CONCLUSIONS: The results demonstrated that the phenome can be further analyzed by a generative model, which can discover probabilistic associations between drugs and therapeutic uses. In this regard, LDA serves as an enrichment tool to explore new uses of existing drugs by narrowing down the search space. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2105-15-267) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4137076
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41370762014-08-19 A phenome-guided drug repositioning through a latent variable model Bisgin, Halil Liu, Zhichao Fang, Hong Kelly, Reagan Xu, Xiaowei Tong, Weida BMC Bioinformatics Methodology Article BACKGROUND: The phenome represents a distinct set of information in the human population. It has been explored particularly in its relationship with the genome to identify correlations for diseases. The phenome has been also explored for drug repositioning with efforts focusing on the search space for the most similar candidate drugs. For a comprehensive analysis of the phenome, we assumed that all phenotypes (indications and side effects) were inter-connected with a probabilistic distribution and this characteristic may offer an opportunity to identify new therapeutic indications for a given drug. Correspondingly, we employed Latent Dirichlet Allocation (LDA), which introduces latent variables (topics) to govern the phenome distribution. RESULTS: We developed our model on the phenome information in Side Effect Resource (SIDER). We first developed a LDA model optimized based on its recovery potential through perturbing the drug-phenotype matrix for each of the drug-indication pairs where each drug-indication relationship was switched to “unknown” one at the time and then recovered based on the remaining drug-phenotype pairs. Of the probabilistically significant pairs, 70% was successfully recovered. Next, we applied the model on the whole phenome to narrow down repositioning candidates and suggest alternative indications. We were able to retrieve approved indications of 6 drugs whose indications were not listed in SIDER. For 908 drugs that were present with their indication information, our model suggested alternative treatment options for further investigations. Several of the suggested new uses can be supported with information from the scientific literature. CONCLUSIONS: The results demonstrated that the phenome can be further analyzed by a generative model, which can discover probabilistic associations between drugs and therapeutic uses. In this regard, LDA serves as an enrichment tool to explore new uses of existing drugs by narrowing down the search space. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2105-15-267) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-08 /pmc/articles/PMC4137076/ /pubmed/25103881 http://dx.doi.org/10.1186/1471-2105-15-267 Text en © Bisgin et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology Article
Bisgin, Halil
Liu, Zhichao
Fang, Hong
Kelly, Reagan
Xu, Xiaowei
Tong, Weida
A phenome-guided drug repositioning through a latent variable model
title A phenome-guided drug repositioning through a latent variable model
title_full A phenome-guided drug repositioning through a latent variable model
title_fullStr A phenome-guided drug repositioning through a latent variable model
title_full_unstemmed A phenome-guided drug repositioning through a latent variable model
title_short A phenome-guided drug repositioning through a latent variable model
title_sort phenome-guided drug repositioning through a latent variable model
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137076/
https://www.ncbi.nlm.nih.gov/pubmed/25103881
http://dx.doi.org/10.1186/1471-2105-15-267
work_keys_str_mv AT bisginhalil aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT liuzhichao aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT fanghong aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT kellyreagan aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT xuxiaowei aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT tongweida aphenomeguideddrugrepositioningthroughalatentvariablemodel
AT bisginhalil phenomeguideddrugrepositioningthroughalatentvariablemodel
AT liuzhichao phenomeguideddrugrepositioningthroughalatentvariablemodel
AT fanghong phenomeguideddrugrepositioningthroughalatentvariablemodel
AT kellyreagan phenomeguideddrugrepositioningthroughalatentvariablemodel
AT xuxiaowei phenomeguideddrugrepositioningthroughalatentvariablemodel
AT tongweida phenomeguideddrugrepositioningthroughalatentvariablemodel